Cerenome Launches CNSide® CSF Molecular Profile Tests

Barchart · 2d ago

HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.